NCT02829775View on ClinicalTrials.gov

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Chronic Myelogenous LeukemiaMalignant MelanomaRenal Cell Carcinoma
Interventions
DRUG

Pegylated Interferon Alfa-2a

Participants will maintain the same dose they were receiving in the parent protocol.

DRUG

Recombinant Interferon Alfa 2a

Participants will maintain the same dose they were receiving in the parent protocol.

Trial Locations (8)

1757

Sofia

4091

Durban

46009

Valencia

125167

Moscow

129110

Moscow

B3H 2Y9

Halifax

226 014

Lucknow

040 66

Košice

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02829775 - A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | Biotech Hunter | Biotech Hunter